Cargando…

Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics

BACKGROUND: Langerhans cell histiocytosis (LCH) is a proliferative disorder in which abnormal Langerhans cell (LC)-like cells (LCH cells) intermingle with inflammatory cells. Whether LCH is reactive or neoplastic remains a controversial matter. We recently described Merkel cell polyomavirus (MCPyV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Ichiro, Oh, Yukiko, Morimoto, Akira, Sano, Hitoshi, Kanzaki, Susumu, Matsushita, Michiko, Iwasaki, Takeshi, Kuwamoto, Satoshi, Kato, Masako, Nagata, Keiko, Hayashi, Kazuhiko, Imashuku, Shinsaku, Gogusev, Jean, Jaubert, Francis, Oka, Takashi, Yoshino, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475324/
https://www.ncbi.nlm.nih.gov/pubmed/26097443
http://dx.doi.org/10.1186/s12014-015-9089-2
_version_ 1782377448962260992
author Murakami, Ichiro
Oh, Yukiko
Morimoto, Akira
Sano, Hitoshi
Kanzaki, Susumu
Matsushita, Michiko
Iwasaki, Takeshi
Kuwamoto, Satoshi
Kato, Masako
Nagata, Keiko
Hayashi, Kazuhiko
Imashuku, Shinsaku
Gogusev, Jean
Jaubert, Francis
Oka, Takashi
Yoshino, Tadashi
author_facet Murakami, Ichiro
Oh, Yukiko
Morimoto, Akira
Sano, Hitoshi
Kanzaki, Susumu
Matsushita, Michiko
Iwasaki, Takeshi
Kuwamoto, Satoshi
Kato, Masako
Nagata, Keiko
Hayashi, Kazuhiko
Imashuku, Shinsaku
Gogusev, Jean
Jaubert, Francis
Oka, Takashi
Yoshino, Tadashi
author_sort Murakami, Ichiro
collection PubMed
description BACKGROUND: Langerhans cell histiocytosis (LCH) is a proliferative disorder in which abnormal Langerhans cell (LC)-like cells (LCH cells) intermingle with inflammatory cells. Whether LCH is reactive or neoplastic remains a controversial matter. We recently described Merkel cell polyomavirus (MCPyV) as a possible causative agent of LCH and proposed interleukin-1 loop model: LCH is a reactive disorder with an underlying oncogenic potential and we now propose to test this theory by looking for acute markers of inflammation. We detected MCPyV-DNA in the peripheral blood cells of patients with high-risk organ-type (LCH-risk organ (RO) (+)) but not those with non–high-risk organ-type LCH (LCH-RO (−)); this difference was significant. LCH-RO (−) is further classified by its involvement of either a single organ system (SS-LCH) or multiple organ systems (MS-LCH). In patients with LCH-RO (−), MCPyV-DNA sequences were present in LCH tissues, and significant differences were observed between LCH tissues and control tissues associated with conditions such as dermatopathic lymphadenopathy and reactive lymphoid hyperplasia. Although MCPyV causes subclinical infection in nearly all people and 22 % of healthy adults will harbor MCPyV in their buffy coats, circulating monocytes could serve as MCPyV reservoirs and cause disseminated skin lesions. METHODS: Plasma sample from 12 patients with LCH-RO (−) (5 MS-LCH and 7 SS-LCH) and 5 non-LCH patients were analyzed by peptidomics. Mass spectrometry (MS) spectra were acquired and peptides exhibiting quantitative differences between MS-LCH and SS-LCH patients were targeted. RESULTS: One new candidate biomarker, m/z 3145 was selected and identified after obtaining a MS/MS fragmentation pattern using liquid chromatography-MS/MS. This peak was identified as a proteolytic fragment derived from inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4, [PDB: Q14624]). CONCLUSIONS: Peptidomics of LCH have revealed that the level of acute-phase ITIH4 distinguishes MS-LCH-RO (−) from SS-LCH-RO (−). Acute-phase proteins serve non-specific, physiological immune functions within the innate immune system. LCH may be a reactive disorder with both underlying neoplastic potential of antigen presenting cells harboring BRAF mutations and hyper-immunity of other inflammatory cells against MCPyV infection. Among LCH-RO (−), MCPyV-DNA sequences were present in both MS-LCH tissues and SS-LCH tissues without significant differences. ITIH4 may show that LCH activity or LCH subtypes correlates with the systemic or localized reactions of MCPyV infection.
format Online
Article
Text
id pubmed-4475324
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44753242015-06-21 Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics Murakami, Ichiro Oh, Yukiko Morimoto, Akira Sano, Hitoshi Kanzaki, Susumu Matsushita, Michiko Iwasaki, Takeshi Kuwamoto, Satoshi Kato, Masako Nagata, Keiko Hayashi, Kazuhiko Imashuku, Shinsaku Gogusev, Jean Jaubert, Francis Oka, Takashi Yoshino, Tadashi Clin Proteomics Research BACKGROUND: Langerhans cell histiocytosis (LCH) is a proliferative disorder in which abnormal Langerhans cell (LC)-like cells (LCH cells) intermingle with inflammatory cells. Whether LCH is reactive or neoplastic remains a controversial matter. We recently described Merkel cell polyomavirus (MCPyV) as a possible causative agent of LCH and proposed interleukin-1 loop model: LCH is a reactive disorder with an underlying oncogenic potential and we now propose to test this theory by looking for acute markers of inflammation. We detected MCPyV-DNA in the peripheral blood cells of patients with high-risk organ-type (LCH-risk organ (RO) (+)) but not those with non–high-risk organ-type LCH (LCH-RO (−)); this difference was significant. LCH-RO (−) is further classified by its involvement of either a single organ system (SS-LCH) or multiple organ systems (MS-LCH). In patients with LCH-RO (−), MCPyV-DNA sequences were present in LCH tissues, and significant differences were observed between LCH tissues and control tissues associated with conditions such as dermatopathic lymphadenopathy and reactive lymphoid hyperplasia. Although MCPyV causes subclinical infection in nearly all people and 22 % of healthy adults will harbor MCPyV in their buffy coats, circulating monocytes could serve as MCPyV reservoirs and cause disseminated skin lesions. METHODS: Plasma sample from 12 patients with LCH-RO (−) (5 MS-LCH and 7 SS-LCH) and 5 non-LCH patients were analyzed by peptidomics. Mass spectrometry (MS) spectra were acquired and peptides exhibiting quantitative differences between MS-LCH and SS-LCH patients were targeted. RESULTS: One new candidate biomarker, m/z 3145 was selected and identified after obtaining a MS/MS fragmentation pattern using liquid chromatography-MS/MS. This peak was identified as a proteolytic fragment derived from inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4, [PDB: Q14624]). CONCLUSIONS: Peptidomics of LCH have revealed that the level of acute-phase ITIH4 distinguishes MS-LCH-RO (−) from SS-LCH-RO (−). Acute-phase proteins serve non-specific, physiological immune functions within the innate immune system. LCH may be a reactive disorder with both underlying neoplastic potential of antigen presenting cells harboring BRAF mutations and hyper-immunity of other inflammatory cells against MCPyV infection. Among LCH-RO (−), MCPyV-DNA sequences were present in both MS-LCH tissues and SS-LCH tissues without significant differences. ITIH4 may show that LCH activity or LCH subtypes correlates with the systemic or localized reactions of MCPyV infection. BioMed Central 2015-06-18 /pmc/articles/PMC4475324/ /pubmed/26097443 http://dx.doi.org/10.1186/s12014-015-9089-2 Text en © Murakami et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Murakami, Ichiro
Oh, Yukiko
Morimoto, Akira
Sano, Hitoshi
Kanzaki, Susumu
Matsushita, Michiko
Iwasaki, Takeshi
Kuwamoto, Satoshi
Kato, Masako
Nagata, Keiko
Hayashi, Kazuhiko
Imashuku, Shinsaku
Gogusev, Jean
Jaubert, Francis
Oka, Takashi
Yoshino, Tadashi
Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics
title Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics
title_full Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics
title_fullStr Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics
title_full_unstemmed Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics
title_short Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics
title_sort acute-phase itih4 levels distinguish multi-system from single-system langerhans cell histiocytosis via plasma peptidomics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475324/
https://www.ncbi.nlm.nih.gov/pubmed/26097443
http://dx.doi.org/10.1186/s12014-015-9089-2
work_keys_str_mv AT murakamiichiro acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT ohyukiko acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT morimotoakira acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT sanohitoshi acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT kanzakisusumu acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT matsushitamichiko acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT iwasakitakeshi acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT kuwamotosatoshi acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT katomasako acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT nagatakeiko acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT hayashikazuhiko acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT imashukushinsaku acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT gogusevjean acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT jaubertfrancis acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT okatakashi acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics
AT yoshinotadashi acutephaseitih4levelsdistinguishmultisystemfromsinglesystemlangerhanscellhistiocytosisviaplasmapeptidomics